Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

More phase 3 data reported for abrocitinib for atopic dermatitis

Key clinical point: Monotherapy with once-daily oral abrocitinib is effective and well tolerated for atopic dermatitis.

Major finding: At 12 weeks, 38% of patients on abrocitinib at 200 mg once daily were clear or almost clear, compared with 9% of placebo-treated controls.

Study details: JADE-MONO-2 was a randomized, double-blind, placebo-controlled, 12-week, pivotal Phase 3 clinical trial in 391 adolescents and adults with moderate to severe atopic dermatitis.

Disclosures: The presenter reported receiving research grants from Pfizer, the study sponsor, and close to two dozen other pharmaceutical companies.

Citation:

Gooderham M. AAD 2020.